Patents by Inventor Tomas ROUSE

Tomas ROUSE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-IFNAR1 DOSING REGIME FOR SUBCUTANEOUS INJECTION
    Publication number: 20240400699
    Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.
    Type: Application
    Filed: May 15, 2024
    Publication date: December 5, 2024
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE
  • DOSE
    Publication number: 20240360231
    Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.
    Type: Application
    Filed: February 27, 2024
    Publication date: October 31, 2024
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE
  • TREATMENT OF LUPUS NEPHRITIS
    Publication number: 20220348669
    Abstract: The disclosure relates to methods and compositions for the treatment of lupus nephritis. Specifically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.
    Type: Application
    Filed: April 22, 2022
    Publication date: November 3, 2022
    Applicant: AstraZeneca AB
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE, Teodora TRASIEVA, Wendy WHITE, Dominic SINIBALDI, Madhu RAMASWAMY, Paul NEWCOMBE
  • DOSE
    Publication number: 20220340669
    Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.
    Type: Application
    Filed: April 22, 2022
    Publication date: October 27, 2022
    Applicant: AstraZeneca AB
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE